UNIGE document Scientific Article - Review
previous document  unige:21272  next document
add to browser collection
Title

Sinusoidal obstruction syndrome and nodular regenerative hyperplasia are frequent oxaliplatin-associated liver lesions and partially prevented by bevacizumab in patients with hepatic colorectal metastasis

Authors
Lauwers, Gregory Y.
Wang, Huamin
Tanabe, Kenneth
Zhu, Andrew X.
Brezault, Catherine
Soubrane, Olivier
show hidden authors show all authors [1 - 12]
Published in Histopathology. 2010, vol. 56, no. 4, p. 430-439
Abstract AIMS: Because of its efficacy, oxaliplatin (OX) is increasingly used as a chemotherapeutic agent in the treatment of colorectal liver metastases (CRLM). Oxaliplatin-associated liver toxicity has been reported and can affect clinical practice, but studies on its prevalence and a full pathological description are lacking. The aims of this study were to fill this gap by providing, from a pathologist's perspective, a detailed assessment of the spectrum of hepatic lesions associated with OX, to suggest a scoring system to quantify them, and to investigate the protective effect of bevacizumab against OX-associated damage. METHODS AND RESULTS: The spectrum of oxaliplatin-associated liver lesions was investigated in a multi-institutional series of surgically resected CRLM (n = 385). Among 274 patients treated by OX, 54% had moderate/severe sinusoidal obstruction syndrome (SOS). Peliosis, centrilobular perisinusoidal/venular fibrosis and nodular regenerative hyperplasia (NRH) developed in 10.6%, 47% and 24.5%, respectively. The 111 patients treated by surgery alone had no lesions. Hepatic lesions were less severe in patients treated with OX/bevacizumab (n = 70) compared with the group treated by OX alone (n = 204), with an incidence of moderate/severe SOS (31.4% versus 62.2%), peliosis (4.3% versus 14.6%), NRH (11.4% versus 28.9%, respectively) and centrilobular/venular fibrosis (31.4% versus 52%, respectively) (P < 0.001). CONCLUSIONS: Pathologists should be aware of the distinctive lesions associated with OX and of their high prevalence. OX-related lesions are less frequent in patients treated with bevacizumab, suggesting that this drug has a preventive effect. Uniform criteria for diagnosis and grading of OX-associated lesions should help to include histological data in the optimal multidisciplinary management of CRLM.
Keywords AdultAgedAged, 80 and overAntibodies, Monoclonal/administration & dosage/*therapeutic useAntibodies, Monoclonal, HumanizedAntineoplastic Agents/*adverse effects/pharmacology/therapeutic useAntineoplastic Combined Chemotherapy Protocols/*therapeutic useColorectal Neoplasms/*pathologyFemaleHepatic Veno-Occlusive Disease/drug therapy/*etiology/surgeryHumansHyperplasia/chemically induced/etiology/pathologyLiver Neoplasms/*drug therapy/pathology/*secondary/surgeryMaleMiddle AgedMulticenter Studies as TopicOrganoplatinum Compounds/administration & dosage/*adverse effectsRetrospective Studies
Identifiers
PMID: 20459550
Full text
Structures
Research groups Hépatologie chirurgicale (327)
Métastases du foie (657)
Citation
(ISO format)
RUBBIA-BRANDT, Laura et al. Sinusoidal obstruction syndrome and nodular regenerative hyperplasia are frequent oxaliplatin-associated liver lesions and partially prevented by bevacizumab in patients with hepatic colorectal metastasis. In: Histopathology, 2010, vol. 56, n° 4, p. 430-439. https://archive-ouverte.unige.ch/unige:21272

226 hits

0 download

Update

Deposited on : 2012-05-23

Export document
Format :
Citation style :